Published in Clin Cancer Res on February 01, 2000
(124)I-huA33 antibody PET of colorectal cancer. J Nucl Med (2011) 2.01
A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. Blood (2009) 1.66
The development of immunoconjugates for targeted cancer therapy. Nat Rev Clin Oncol (2014) 1.49
Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl Med Biol (2007) 1.44
Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci U S A (2003) 1.18
A semiempirical model of tumor pretargeting. Bioconjug Chem (2008) 1.16
Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer (2008) 1.12
Clinical radioimmunotherapy--the role of radiobiology. Nat Rev Clin Oncol (2011) 1.10
Cancer radioimmunotherapy. Immunotherapy (2011) 1.10
Radioimmunotherapy of human tumours. Nat Rev Cancer (2015) 1.07
Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res (2008) 1.07
Have we overestimated the benefit of human(ized) antibodies? MAbs (2010) 1.05
Reduced antibody response to streptavidin through site-directed mutagenesis. Protein Sci (2001) 1.05
Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging. Nucl Med Biol (2010) 0.98
Characterization of poultry egg-white avidins and their potential as a tool in pretargeting cancer treatment. Biochem J (2003) 0.97
Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. Semin Nucl Med (2010) 0.96
90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy. Bioconjug Chem (2011) 0.96
Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49. Eur J Nucl Med Mol Imaging (2004) 0.88
Biodistribution and clearance of small molecule hapten chelates for pretargeted radioimmunotherapy. Mol Imaging Biol (2011) 0.88
Mechanisms of action of therapeutic antibodies for cancer. Mol Immunol (2015) 0.87
Pretargeted radioimmunotherapy for hematologic and other malignancies. Cancer Biother Radiopharm (2010) 0.86
Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants. Bioconjug Chem (2010) 0.86
Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody. Eur J Nucl Med Mol Imaging (2005) 0.86
Biochemical and biological characterization of a new oxidized avidin with enhanced tissue binding properties. J Biol Chem (2010) 0.86
Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT). Br J Cancer (2003) 0.86
Improvement of radioimmunotherapy using pretargeting. Front Oncol (2013) 0.85
Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma. Clin Cancer Res (2011) 0.84
Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry. Mol Pharm (2013) 0.84
Mutations for decreasing the immunogenicity and maintaining the function of core streptavidin. Protein Sci (2013) 0.84
Avidin-biotin system pretargeting radioimmunoimaging and radioimmunotherapy and its application in mouse model of human colon carcinoma. World J Gastroenterol (2005) 0.82
Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer. Clin Cancer Res (2008) 0.81
Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies. Eur J Nucl Med Mol Imaging (2011) 0.79
Bispecific Her2 × cotinine antibody in combination with cotinine-(histidine)2-iodine for the pre-targeting of Her2-positive breast cancer xenografts. J Cancer Res Clin Oncol (2013) 0.78
Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells. Cancer Immunol Immunother (2013) 0.76
Synthesis and cytotoxicity of a biotinylated CC-1065 analogue. BMC Chem Biol (2002) 0.75
Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies. ScientificWorldJournal (2014) 0.75
Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery. J Control Release (2015) 0.75
Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med (1980) 9.64
Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med (1979) 3.59
Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood (1981) 3.03
High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res (2001) 2.90
Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med (1981) 2.61
Cation transport in Escherichia coli. VII. Potassium requirement for phosphate uptake. J Gen Physiol (1967) 2.52
Biological behavior of human breast carcinoma-associated antigens expressed during cellular proliferation. Cancer Res (1983) 2.46
MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med (1999) 2.41
One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood (1977) 2.36
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood (2000) 2.11
Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol (1996) 2.08
Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol (1996) 2.05
Apolipoprotein E genotype: utility in clinical practice in Alzheimer's disease. J Am Geriatr Soc (1996) 2.03
The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res (2001) 2.01
A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci U S A (1981) 2.00
Lipopolysaccharide induces activation of CD14-associated protein tyrosine kinase p53/56lyn. J Biol Chem (1993) 1.95
Alterations of the lymphocyte-specific protein tyrosine kinase (p56lck) during T-cell activation. Mol Cell Biol (1988) 1.90
Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. J Mol Biol (1996) 1.90
Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res (1986) 1.86
Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials. J Nucl Med (1992) 1.84
Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res (1993) 1.82
Post-translational alterations of the tyrosine kinase p56lck in response to activators of protein kinase C. Oncogene Res (1988) 1.80
Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol (2001) 1.73
Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application. Cancer Res (2000) 1.71
Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet (1995) 1.69
Imaging and treatment of B-cell lymphoma. J Nucl Med (1990) 1.68
Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. Cancer Biother Radiopharm (2000) 1.65
The Edinburgh study of growth and development in children with sex chromosome abnormalities. Birth Defects Orig Artic Ser (1979) 1.64
Role of oxidants and antioxidants in the induction of AP-1, NF-kappaB, and glutathione S-transferase gene expression. J Biol Chem (1996) 1.61
Form and function of the corpus luteum during the human menstrual cycle. Ultrasound Obstet Gynecol (2005) 1.60
99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma. J Nucl Med (2001) 1.59
Overview of animal studies comparing radioimmunotherapy with dose equivalent external beam irradiation. Radiother Oncol (1992) 1.57
Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res (1998) 1.57
A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood (2001) 1.52
Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res (2000) 1.52
Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer. J Nucl Med (1992) 1.49
A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations. Int J Cancer (1982) 1.47
Outpatient treatment with (131)I-anti-B1 antibody: radiation exposure to family members. J Nucl Med (2001) 1.47
Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res (1996) 1.47
MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions--radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee. J Nucl Med (1999) 1.44
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol (2007) 1.44
Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med (1979) 1.44
Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol (2000) 1.43
Dosimetry of rhenium-186-labeled monoclonal antibodies: methods, prediction from technetium-99m-labeled antibodies and results of phase I trials. J Nucl Med (1993) 1.42
Isolation of the mouse mammary tumor virus sequences not transmitted as germinal provirus in the C3H and RIII mouse strains. J Virol (1977) 1.39
Approaches to preventing or reversing platelet alloimmunization using animal models. Transfusion (1988) 1.39
Some problems in the skeletal dosimetry of bone-seeking radionuclides. Health Phys (1999) 1.39
In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology (1995) 1.38
A mouse model for calculating cross-organ beta doses from yttrium-90-labeled immunoconjugates. Cancer (1994) 1.37
Expression of single-chain Fv-Fc fusions in Pichia pastoris. J Immunol Methods (2001) 1.36
Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng Des Sel (2004) 1.33
Magnetic resonance imaging of myositis ossificans: analysis of seven cases. Skeletal Radiol (1992) 1.33
High level functional engraftment of severe combined immunodeficient mice with human peripheral blood lymphocytes following pretreatment with radiation and anti-asialo GM1. J Immunol Methods (1994) 1.32
Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood (1999) 1.31
Infectious agammaglobulinemia: transmission of immunodeficiency with grafts of agammaglobulinemic cells. J Exp Med (1974) 1.29
Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer (1998) 1.25
The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation (1992) 1.25
Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. Cancer Res (1988) 1.25
Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst (1999) 1.25
MicroRNAs 10a and 10b are potent inducers of neuroblastoma cell differentiation through targeting of nuclear receptor corepressor 2. Cell Death Differ (2011) 1.24
Osteochondritis dissecans of the knee: value of MR imaging in determining lesion stability and the presence of articular cartilage defects. AJR Am J Roentgenol (1990) 1.24
Expression in COS cells of a mouse-human chimaeric B72.3 antibody. Protein Eng (1987) 1.23
The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood (1993) 1.22
Impaired lymphocyte transformation in intestinal lymphangiectasia: evidence for at least two functionally distinct lymphocyte populations in man. J Clin Invest (1972) 1.22
Quantitation of RNA tumor viruses and viruslike particles in human milk by hybridization to polyadenylic acid sequences. Science (1973) 1.21
Chronic cutaneous graft-versus-host disease in man. Am J Pathol (1978) 1.21
Analysis of late infections in 89 long-term survivors of bone marrow transplantation. Blood (1979) 1.21
An historical and developmental analysis of social model programs. J Subst Abuse Treat (1998) 1.20
Klinefelter's syndrome in adolescence. Arch Dis Child (1982) 1.20
Mason-Pfizer virus RNA genome: relationship to the RNA of morphologically similar isolates and other oncornaviruses. J Virol (1976) 1.20
A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Res (2000) 1.19
Automatic registration and alignment on a template of cardiac stress and rest reoriented SPECT images. IEEE Trans Med Imaging (1997) 1.19
Computed tomographic mammography using a conventional body scanner. AJR Am J Roentgenol (1982) 1.19
Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res (1993) 1.18
Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin. J Nucl Med (2000) 1.17
Cyclosporin A and methotrexate in canine marrow transplantation: engraftment, graft-versus-host disease, and induction of intolerance. Transplantation (1982) 1.17
Deposition of IgM and complement at the dermoepidermal junction in acute and chronic cutaneous graft-vs-host disease in man. J Immunol (1978) 1.17
Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice. J Nucl Med (1988) 1.17
CD16+ monocytes in patients with cancer: spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor. Blood (1995) 1.16
Vincristine neurotoxicity. N Engl J Med (1972) 1.15
Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res (2000) 1.15
Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection. Gene Ther (2010) 1.14
Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis. Mol Immunol (1999) 1.14
Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol (1998) 1.13
Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody. Cancer Res (1983) 1.13
Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. Protein Eng Des Sel (2007) 1.13
Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer (2008) 1.12
Aplastic anemia treated by allogeneic bone marrow transplantation: a report on 49 new cases from Seattle. Blood (1976) 1.11
Characterization of mouse mammary tumor viruses propagated in heterologous cells. Cancer Res (1977) 1.11